Maria Baer is an Oncology physician. OpenAlex indexes 914 publications with 24,001 citations (h-index 74); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
22 S Greene St
Baltimore, MD 212011544
Telephone
410-328-8708Registry record last updated 6 Sept 2011.
Clinical trials
- Decitabine and Talazoparib in Untreated AML and R/R AML
Sponsor: University of Maryland, Baltimore
- Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720
Sponsor: Alliance for Clinical Trials in Oncology
- Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- SANOFI-AVENTIS U.S. LLCProgram year20241 payment
- Pharmacyclics LLC, An AbbVie CompanyProgram year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD
Baltimore Va Medical Center
FY2026I01BX005120 - Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD
Baltimore Va Medical Center
FY2024I01BX005120 - Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD
Baltimore Va Medical Center
FY2023I01BX005120
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
New England Journal of Medicine
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”